Prognostic Value of 177Lutetium-PSMA Single Photon Emission Tomography and Timing of Response

Starting soon

Conditions studied: Therapy-Associated Cancer

In brief

177Lutetium-PSMA-617 is an established treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). Early response assessment is critical for optimizing patient management. Response Evaluation Criteria in Prostate Imaging (RECIP) 1.0, initially developed for Positon Emission Tomography (PET) with 68Ga-PSMA, have demonstrated prognostic value, particularly after two treatment cycles. Recent studies suggest that SPECT at cycle 2 provides prognostic information, although it reflects only the first treatment cycle, whereas PET-based RECIP, assessed after cycle 2, captures the effect of two cycles. This study aims to evaluate the prognostic value of quantitative 177Lu-PSMA-SPECT biomarkers and determine the optimal timing for RECIP-based assessment.

Key facts

Study ID

NCT07643935

Run by

Central Hospital, Nancy, France

People needed

280

Starts

2026-07-01

Expected to finish

2026-12-01

Last updated by the study team

2026-06-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with metastatic castration-resistant cancer who received at least two cycles of 177Lu-PSMA

You may not qualify if…

• Patients who refused to have their data used for research purposes

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.